Split Dosing of Oral Methotrexate for Rheumatoid Arthritis
For patients experiencing intolerance to once-weekly oral methotrexate, split the weekly dose into 2-3 divided doses given at 12-hour intervals over 24 hours (e.g., 2.5 mg every 12 hours for 3 doses to achieve 7.5 mg weekly). This approach is conditionally recommended before switching to alternative DMARDs or subcutaneous administration 1.
When to Consider Split Dosing
Split dosing should be implemented specifically for:
- Patients not tolerating weekly oral methotrexate (gastrointestinal side effects, nausea, decreased appetite, gastritis) 1
- Patients on higher doses (15-25 mg/week) where bioavailability becomes an issue 2
The 2021 ACR guidelines explicitly state that split dosing over 24 hours, along with increased folic/folinic acid supplementation, is preferred over switching to alternative DMARDs due to methotrexate's proven efficacy, long-term safety profile, and low cost 1.
Specific Split Dosing Regimen
The FDA label provides the exact schedule 3:
- Divided oral dosages of 2.5 mg at 12-hour intervals for 3 doses given as a course once weekly
- This can be adjusted proportionally for higher doses (e.g., for 15 mg weekly: 5 mg every 12 hours for 3 doses)
Evidence Supporting Split Dosing
Bioavailability Advantage
Split dosing demonstrates 28% higher bioavailability compared to single-dose administration at higher doses (25-35 mg weekly), with mean bioavailability of 0.90 versus 0.76 for single doses 2. This pharmacokinetic advantage is particularly relevant when escalating beyond 15 mg weekly.
Clinical Efficacy
A 2018 randomized trial showed that oral split-dose methotrexate achieved 49% low disease activity at 24 weeks, comparable to parenteral administration (47%) and superior to single oral dosing (36%), with the highest treatment adherence at 69% 4.
Side Effect Profile
A 2022 study demonstrated that alternate-day split dosing significantly reduced:
- Gastritis: 63.4% → 41.5%
- Nausea: 51.2% → 35.8%
- Decreased appetite: 74.0% → 60.2%
- Hepatotoxicity: 14.6% → 5.7%
Importantly, disease activity remained equivalent between regimens 5.
Important Caveats
The twice-weekly regimen (spreading doses across different days of the week) does NOT show superiority. A 2002 double-blind trial found no advantage of methotrexate given twice weekly versus once weekly for ACR20/50 responses 6. The key distinction is that effective split dosing occurs within a 24-hour period, not across multiple days of the week.
One older study suggested daily dosing might stabilize C-reactive protein better 7, but this approach has not been validated in modern guidelines and carries theoretical concerns about cumulative toxicity.
Clinical Algorithm
Start with once-weekly oral dosing (7.5 mg, escalating to ≥15 mg within 4-6 weeks) 1
If intolerance develops (GI symptoms, nausea, decreased appetite):
- Switch to split dosing: divide weekly dose into 2.5 mg increments every 12 hours over 24 hours
- Increase folic acid supplementation simultaneously 1
If split dosing fails or inadequate response despite optimization:
- Switch to subcutaneous administration 1
- Consider alternative DMARDs only after exhausting methotrexate optimization strategies
For doses >20 mg/week: Split dosing becomes increasingly important due to saturable oral absorption at higher single doses 2
The EULAR 2020 guidelines emphasize that methotrexate should be escalated to approximately 0.3 mg/kg weekly (20-25 mg in Western populations) within 4-6 weeks, with appropriate folic acid supplementation 8. Split dosing facilitates achieving these therapeutic doses while maintaining tolerability.